Table 1.
Serum and urine biomarkers analyzed in this study.
| Biomarkers | Manufacturer | Biological Process [22] |
|---|---|---|
| Primary Predictors | ||
| Serum COMP (sCOMP) | Biovendor | Cartilage degradation |
| Serum hyaluronan (sHA) | Corgenix | Osteophyte burden, synovitis |
| Serum MMP-3 (sMMP3) | Invitrogen | Total (active and inactive) metalloprotease involved with joint tissue degradation |
| Urine CTXII (uCTXII) | Biovendor | Type II collagen degradation |
| Exploratory Predictors | ||
| Serum PIIANP (sPIIANP) | Merck Group/Millipore | Type II collagen synthesis |
| Serum CTXI (sCTXI) | IDS | Bone resorption |
| Serum CS846 (sCS846) | IBEX | Cartilage aggrecan synthesis/turnover |
| Serum C2C (sC2C) | IBEX | Type II collagen degradation |
| Serum CPII (sCPIl) | IBEX | Type II collagen synthesis |
| Serum/Urine NTXI (sNTXI/uNTXI) | ALERE - Osteomark | Bone resorption |
| Serum/Urine Coll2 1 NO2 (sColl21 NO2/uColl21 NO2) | Artialis | Type II collagen degradation and inflammation |
| Serum/Urine C1,2C (sC12C/uC12C) | IBEX | Types 1 and II collagen degradation |
Abbreviations: COMP, cartilage oligomeric matrix protein; CTXII, C-terminal crosslinked telopeptide type II collagen; PIIANP, type IIA procollagen amino terminal propeptide; CTXI, C-terminal crosslinked telopeptide of type I collagen; CS846, chondroitin sulfate 846 epitope; C2C, Collagen Type II Cleavage; CPII, C-propeptide of type II collagen; NTXI, N-telopeptide of type I collagen. All biomarker assays were performed by LabCorp Clinical Trials, a Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP) certified division within LabCorp, with the exception of urine Col2-1 NO2, which was measured by Artialis, a Good Laboratory Practice-certified facility.